Abstract
Background: Mood disorders, consisting of unipolar and bipolar depression, are complex diseases characterized by depressed mood and anhedonia. These core symptoms are accompanied in a varying manner by anxiety, several neurovegetative symptoms and cognitive impairment. Mood disorders are characterized by decreases in neurogenesis, alteration in synaptic structure and synaptic transmission, all of them regulated by BDNF, a neurotrophin that performs multiple functions in the adult central nervous system. Many evidences show that BDNF is critically decreased in mood disorders and plays an essential role in most anti-depressant treatments. In turn, the transcription factor NF-kB has recently emerged as an important player in the pathophysiology of depression, with roles in neurogenesis, synaptic transmission and plasticity.
Methodology: We review the bidirectional interactions between BDNF and NF-kB signaling pathways. Results and Conclusions: We discuss a potential beneficial effect of a positive feedback loop between BDNF and NF-kB activated pathways in antidepressant action. This could be transduced into the identification of downstream NF-kB gene targets able to potentiate antidepressant mechanisms, thus guiding the development of novel and faster acting antidepressant drugs.Keywords: BDNF, NF-κB, mood disorders, neurogenesis, plasticity, anhedonia.
Current Pharmaceutical Design
Title:BDNF/NF-κB Signaling in the Neurobiology of Depression
Volume: 23 Issue: 21
Author(s): Ariel Caviedes, Carlos Lafourcade, Claudio Soto and Ursula Wyneken*
Affiliation:
- Laboratorio de Neurociencias, Facultad de Medicina, Universidad de los Andes; Mons. Alvaro del Portillo 12.455, Las Condes; Santiago,Chile
Keywords: BDNF, NF-κB, mood disorders, neurogenesis, plasticity, anhedonia.
Abstract: Background: Mood disorders, consisting of unipolar and bipolar depression, are complex diseases characterized by depressed mood and anhedonia. These core symptoms are accompanied in a varying manner by anxiety, several neurovegetative symptoms and cognitive impairment. Mood disorders are characterized by decreases in neurogenesis, alteration in synaptic structure and synaptic transmission, all of them regulated by BDNF, a neurotrophin that performs multiple functions in the adult central nervous system. Many evidences show that BDNF is critically decreased in mood disorders and plays an essential role in most anti-depressant treatments. In turn, the transcription factor NF-kB has recently emerged as an important player in the pathophysiology of depression, with roles in neurogenesis, synaptic transmission and plasticity.
Methodology: We review the bidirectional interactions between BDNF and NF-kB signaling pathways. Results and Conclusions: We discuss a potential beneficial effect of a positive feedback loop between BDNF and NF-kB activated pathways in antidepressant action. This could be transduced into the identification of downstream NF-kB gene targets able to potentiate antidepressant mechanisms, thus guiding the development of novel and faster acting antidepressant drugs.Export Options
About this article
Cite this article as:
Caviedes Ariel, Lafourcade Carlos, Soto Claudio and Wyneken Ursula*, BDNF/NF-κB Signaling in the Neurobiology of Depression, Current Pharmaceutical Design 2017; 23 (21) . https://dx.doi.org/10.2174/1381612823666170111141915
DOI https://dx.doi.org/10.2174/1381612823666170111141915 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroinflammation is Associated with Brain Extracellular TAU-Protein Release After Spontaneous Subarachnoid Hemorrhage
Current Drug Targets Ribosome Inactivating Proteins (RIPs) from Momordica charantia for Anti Viral Therapy
Current Molecular Medicine Association between HbA1C (Glycated Hemoglobin) and Clinical Outcomes in Patients with Subarachnoid Hemorrhage After Neuro-intervention
Current Neurovascular Research mTOR Inhibitors in Tuberous Sclerosis Complex
Current Neuropharmacology Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry Stem Cell Therapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Neonatal Ultrasound in Transport
Current Pediatric Reviews Tuberculostatic Drugs Targeting Infections of the Central Nervous System
Anti-Infective Agents Cerebral Palsy: Classification, Etiology and Evolution of Spine Deformity in Children and Adolescents
Current Pediatric Reviews FDG-PET in the Evaluation of Brain Metabolic Changes Induced by Cognitive Stimulation in aMCI Subjects
Current Radiopharmaceuticals Soluble Amyloid-β Levels and Late-Life Depression
Current Pharmaceutical Design Dural Venous Sinuses: What We Need to Know
Current Medical Imaging From Cerebrospinal Fluid Pulsation to Noninvasive Intracranial Compliance and Pressure Measured by MRI Flow Studies
Current Medical Imaging Vagus Nerve Stimulation as a Treatment for Refractory Epilepsy: A 15-Year Experience in an Italian Tertiary – Care Epilepsy Center
Letters in Drug Design & Discovery Venous Collateral Circulation of the Extracranial Cerebrospinal Outflow Routes
Current Neurovascular Research CT and MR Imaging of the Encephalopathic Child
Current Medical Imaging Importance of Aquaporins in the Physiopathology of Brain Edema
Current Pharmaceutical Design Early Hematoma Enlargement in Primary Intracerebral Hemorrhage
Current Drug Targets Cruciferous Plants: Phytochemical Toxicity Versus Cancer Chemoprotection
Mini-Reviews in Medicinal Chemistry